Business Segments (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011	Dec. 31, 2011
Summary of segmental information
Revenues, Principally from Grants	$ 762,851	$ 405,820	$ 1,410,269	$ 1,213,825
Income (Loss) from Operations	(981,677)	(1,932,790)	(2,422,667)	(3,655,636)
Amortization and Depreciation Expense	51,408	54,015	108,753	105,443
Interest Income, Net	1,799	1,473	4,034	3,908
Stock-Based Compensation	117,388	231,869	235,002	388,636
Identifiable Assets	5,911,465		5,911,465		8,223,658
Vaccines/BioDefense [Member]
Summary of segmental information
Revenues, Principally from Grants	710,237	335,029	1,307,842	871,615
Income (Loss) from Operations	(2,144)	(67,425)	(130,509)	52
Amortization and Depreciation Expense	24,954	10,183	52,951	19,872
Stock-Based Compensation	2,130	18,416	4,260	36,832
Identifiable Assets	557,211		557,211		689,266
BioTherapeutics [Member]
Summary of segmental information
Revenues, Principally from Grants	52,614	70,791	102,427	342,210
Income (Loss) from Operations	(481,817)	(1,663,402)	(1,207,859)	(3,044,729)
Amortization and Depreciation Expense	25,892	43,290	54,733	84,491
Stock-Based Compensation	56,194	188,255	112,614	286,508
Identifiable Assets	658,593		658,593		753,767
Corporate [Member]
Summary of segmental information
Revenues, Principally from Grants			1,410,269
Income (Loss) from Operations	(497,716)	(201,963)	(1,084,299)	(610,959)
Amortization and Depreciation Expense	562	542	1,069	1,080
Interest Income, Net	1,799	1,473	4,034	3,908
Stock-Based Compensation	59,064	25,198	118,128	65,296
Identifiable Assets	$ 4,695,661		$ 4,695,661		$ 6,780,625